| Trial ID: | L3793 |
| Source ID: | NCT00430040
|
| Associated Drug: |
Carvedilol Controlled Release (Cr)
|
| Title: |
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00430040/results
|
| Conditions: |
Diabetes Mellitus, Type 2|Hypertension
|
| Interventions: |
DRUG: Carvedilol Controlled Release (CR)|DRUG: lisinopril
|
| Outcome Measures: |
Primary: Change in Brachial Artery Vascular Reactivity, Percent change from baseline in Brachial artery vascular reactivity at 6 months calculated as: (brachial reactivity at 6 months-brachial reactivity at 0 months)/brachial reactivity at 0 month \*100, 6 months | Secondary: Change in Oxidative Stress in Mononuclear Cells (MNC), Percent change from baseline in Reactive Oxygen species (ROS) generation in MNC at 6 months calculated as: (ROS at 6 months-ROS at 0 months)/ROS at 0 month \*100, 6 months
|
| Sponsor/Collaborators: |
Sponsor: University at Buffalo | Collaborators: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
14
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-02
|
| Completion Date: |
2013-05
|
| Results First Posted: |
2024-04-16
|
| Last Update Posted: |
2024-04-16
|
| Locations: |
Diabetes - Endocrinology Center of Western New York, Buffalo, New York, 14221, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00430040
|
